Literature DB >> 22585685

The era of combination therapy in myeloma.

Sagar Lonial, Jonathan L Kaufman.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22585685     DOI： 10.1200/JCO.2011.40.6967

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Authors:  Philippe Rodon; Cyrille Hulin; Brigitte Pegourie; Mourad Tiab; Bruno Anglaret; Lotfi Benboubker; Henry Jardel; Olivier Decaux; Brigitte Kolb; Murielle Roussel; Laurent Garderet; Xavier Leleu; Olivier Fitoussi; Carine Chaleteix; Philippe Casassus; Pascal Lenain; Bruno Royer; Anne Banos; Riad Benramdane; Pascale Cony-Makhoul; Mamoun Dib; Jean Fontan; Anne-Marie Stoppa; Catherine Traullé; Jean-Pierre Vilque; Marie-Odile Pétillon; Claire Mathiot; Thomas Dejoie; Hervé Avet-Loiseau; Philippe Moreau
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

2.  Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.

Authors:  Katelyn G Ponder; Shannon M Matulis; Sadae Hitosugi; Vikas A Gupta; Cathy Sharp; Francis Burrows; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal:  Cancer Biol Ther       Date:  2016-07-02       Impact factor: 4.742

Review 3.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

4.  Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.

Authors:  K T Siu; J Ramachandran; A J Yee; H Eda; L Santo; C Panaroni; J A Mertz; R J Sims Iii; M R Cooper; N Raje
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

5.  Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.

Authors:  Nassera Aouali; Angeliki Broukou; Manon Bosseler; Olivier Keunen; Vincent Schlesser; Bassam Janji; Valerie Palissot; Philippe Stordeur; Guy Berchem
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

Review 6.  Association of response endpoints with survival outcomes in multiple myeloma.

Authors:  S Lonial; K C Anderson
Journal:  Leukemia       Date:  2013-07-19       Impact factor: 11.528
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.